Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

BACKGROUND: Despite the advances of potent oral P2Y(12) inhibitors, their onset of action is delayed, which might have a negative impact on clinical outcome in patients undergoing percutaneous coronary intervention (PCI). Trials conducted in the United States of America have identified cangrelor as...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvarajah, A., Tavenier, A. H., Bor, W. L., Houben, V., Rasoul, S., Kaplan, E., Teeuwen, K., Hofma, S. H., Lipsic, E., Amoroso, G., van Leeuwen, M. A. H., Berg, J. M. ten, van ‘t Hof, A. W. J., Hermanides, R. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199523/
https://www.ncbi.nlm.nih.gov/pubmed/34118880
http://dx.doi.org/10.1186/s12872-021-02093-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199523/
https://www.ncbi.nlm.nih.gov/pubmed/34118880
http://dx.doi.org/10.1186/s12872-021-02093-4

Ejemplares similares